{"id":"NCT00231777","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)","officialTitle":"A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety and Tolerability of IV MK0517 for the Prevention of Postoperative Nausea and Vomiting (PONV)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2005-11","completion":"2005-11","firstPosted":"2005-10-04","resultsPosted":"2010-06-08","lastUpdate":"2015-08-19"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Post-Operative Nausea and Vomiting"],"interventions":[{"type":"DRUG","name":"Comparator: MK0517","otherNames":[]},{"type":"DRUG","name":"Comparator: ondansetron","otherNames":["Zofran"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"A new intravenous medication is being tested for the prevention of the nausea and vomiting that occurs after surgery. This new medication is being compared to another intravenous medication that is already available to patients for this indication.","primaryOutcome":{"measure":"Number of Patients With Clinical Adverse Experiences (CAEs)","timeFrame":"Baseline and 24 hours","effectByArm":[{"arm":"MK0517 Intravenous (IV) 40 mg","deltaMin":125,"sd":null},{"arm":"Ondansetron IV 4 mg","deltaMin":32,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":167},"commonTop":["Nausea","Pruritus","Constipation","Headache","Hypotension"]}}